Healthcare: reloaded...

Elation Health integrated Surescripts’ real-time prescription benefit tool — which gives clinicians immediate access to patient-specific medication coverage and cost data — into its EHR. The partnership aims to improve patients' medication adherence by helping primary care physicians have more meaningful conversations with their patients about prescription affordability during visits.

Most hospitals and payers have publicly posted their pricing information, but experts think that data will remain mostly useless for consumers for at least another five years. Now that the data is available, healthcare software companies must step in and build tools that are personalized and easy to use. That way, consumers can eventually use price transparency data to shop for care.

After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.

Adapting to healthcare consumerism is vital for providers to stay competitive. Shifting from traditional roles to informed consumers requires embracing transparency, technology, and personalized care.

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value. \

GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it's important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.

Key trends such as the resilience of the emerging biopharma space, the complexities of Medicare, and the revolutionary role of data and AI are shaping the future of the industry.

Here are the key trends that will need to be top of mind for provider organizations that are transitioning to VBC, or looking to improve their performance under value-based contracts.

Researchers evaluated the incremental cost-effectiveness ratio (ICER) against the National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold of £20,000–30,000 per QALY gained. Findings from the study showed that radiofrequency renal denervation resulted in a relative risk reduction in clinical events over 10 years (0.80 for stroke, 0.88 for MI, and 0.72 for heart failure) with an increase in health benefit over a patient’s lifetime, adding 0.35 QALYs, at a cost of £4,763, giving an ICER of £13,482 per QALY gained. Findings were robust across tested scenarios, the researchers report.

New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.

Le gras c’est la vie ? Le gras c’est le plaisir répond la science. Trois universitaires décryptent la manière dont les aliments riches s’emparent de nos cerveaux. Ils mettent en avant le rôle de lipides contenus dans les produits gras.

Between 1999 and March 2020, the prevalence of hypertension, diabetes, and smoking was consistently higher among low-income adults. During the study period, the study team observed an increase in hypertension among low-income adults (37.2% to 44.7%), but researchers found no changes in diabetes or obesity. No change in hypertension was seen among higher-income adults, but this group showed increases in diabetes (7.8% to 14.9%) and obesity (33.0%-44.0%). Cigarette use was high among low-income adults and did not change (33.2% to 33.9%); use decreased among higher-income adults (18.6% to 11.5%)

Biomarkers, electronic health records (EHR), genomic data, imaging data, labs, social media, wearable sensors, and more provide enormous new sources of RWD that can aid in new discoveries for the quality, efficacy, and safety of new drug therapies.

A comprehensive approach to obesity management goes beyond prescribing medications for a quick fix.

Amazon has eliminated “a few hundred” jobs across Amazon Pharmacy and One Medical, the company confirmed to MedCity News Wednesday. While some may believe this could lead to Amazon leaving healthcare, one industry expert said that would be an "overly simplistic" takeaway.

A French company is seeking to solve one of the biggest challenges in the emerging cell therapy industry by commercializing an automated system for manufacturing CAR-T at scale. CellQuest, who has recently shared their technology with early-access users, believes their mini-factory can help contract manufacturers reduce costs while scaling-out CAR-T therapies.

The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.

Here we design and construct a sprayable therapeutic hydrogel (HIL@Z/P/H) encapsulating tumor-targeted nanodrug and photosynthetic cyanobacteria (PCC 7942) to prevent tumor recurrence/metastasis while promote wound healing.

Despite the significant challenges to improving U.S. health outcomes while reducing healthcare spending, I am heartened by the exciting ways in which government organizations and the private sector are innovating and deploying new technologies that can achieve these goals.

During a recent webinar, industry leaders agreed that virtual-first health plans have significant potential to cut costs and improve members’ experiences — if executed well. They also noted that employers are more willing than ever to adopt these types of plans.

Elucis enables medical professionals to quickly create, understand, and share complex patient anatomy from computed tomography (CT) and magnetic resonance imaging (MRI) in an immersive 3D environment.

These medical nanomachines are made of a porous silica sphere and have surfaces with specialized components tailored for precise functionality. Constructed from a porous silica-based sphere, these medical nanomachines boast surfaces equipped with specific components designed for precise functions.

The innovator’s mindset is shifting from solving the problems right in front of us to solving problems once considered impossible to fix. The lines between curable and incurable diseases are blurring in surgery because medical devices are scaling up precision and scaling down the size of anatomy that surgeons can operate on.

The label of being ‘non-adherent to medications’ is often considered in a binary (and pejorative) manner; however, medication-taking behaviour is a complicated process with multiple phases and potential barriers. Several methods for detecting non-adherence exist, with many providing complementary rather than gold-standard information. Clinicians need to understand the importance of simplifying medication regimens and encouraging the use of blister packs, whereas health systems need to explore multifaceted, multidisciplinary interventions for complex non-adherence. Multiple interventions for improving medication adherence have proven efficacy, but a one-size-fits-all solution is unlikely to be successful; both precision and population approaches are required and need further evaluation.

By leveraging analytics to optimize the patient experience in clinical trials, patient attrition will decrease, improving clinical outcomes and research goals.